MELD评分联合血清降钙素原评估乙型肝炎相关慢加急性肝衰竭患者短期预后的价值

摘要/Abstract

摘要： 目的探讨MELD评分联合血清降钙素原(PCT)预测乙型肝炎慢加急性肝衰竭(ACLF)患者短期预后的临床价值。方法选取2012年1月至2015年12月于云南省第三人民医院住院的乙型肝炎相关ACLF患者331例,分为生存组(208例)和死亡组(123例),比较两组患者的血清TBil、肌酐(Cr)、国际标准化比值(INR)、血清钠(Na⁺)、MELD评分和血清PCT。计量资料两组间比较采用独立样本Mann-Whitney U检验或t检验,计数资料组间比较采用χ²检验,受试者工作特征曲线下面积(AUC)比较采用正态Z检验。结果死亡组患者的TBil(330.9±81.9) μmol/L比(245.5±67.7) μmol/L、Cr (94.9±23.8) μmol/L比(71.2±29.3) μmol/L、INR(2.5±1.0) μmol/L比(2.1±0.6) μmol/L、MELD评分(26.2±6.5)比(22.0±5.8)、血清PCT浓度(1.3±0.3) μg/L比(0.5±0.2) μg/L均高于生存组,血清Na⁺水平(128.9±14.1) mmol/L比(133.8±9.3) mmol/L低于生存组,差异均有统计学意义(均P＜0.01)。MELD评分、血清PCT预测乙型肝炎相关ACLF患者近期死亡危险性的最佳临界值分别为24.8、0.65 μg/L。MELD评分联合血清PCT判断乙型肝炎相关ACLF短期预后的AUC为0.880,高于单独MELD评分的AUC 0.820和PCT的AUC 0.803,差异均有统计学意义(均P＜0.01)。结论 MELD评分联合血清PCT对乙型肝炎相关ACLF患者短期预后的预测价值良好。

关键词: 肝炎,乙型, 慢加急性肝衰竭, 预后, MELD评分, 降钙素原

Abstract: Objective To investigate the predictive value of combined model for end-stage liver disease (MELD) score and serum procalcitonin (PCT) on the short-term prognosis in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). Methods A total of 331 HBV-related ACLF patients from January 2012 to December 2015 in our hospital were respectively analyzed, and divided into survival group (208 cases) and death group (123 cases) according to the prognosis by 3-month follow-up. Serum total bilirubin (TBil), creatinine (Cr), international normalized ratio (INR), serum PCT and MELD score were measured and compared between the two groups. The capability of MELD score combined with serum PCT was evaluated for predicting the short-term prognosis of HBV-related ACLF patients by receiver operating characteristic (ROC) curve. Results In death group, serum levels of TBIL (330.9±81.9 vs 245.5±67.7 μmol/L), Cr (94.9±23.8 vs 71.2±29.3 μmol/L), PCT (1.3±0.3 vs 0.5±0.2 μg/L), INR (2.5±1.0 vs 2.1±0.6) and MELD score (26.2±6.5 vs 22.0±5.8) were significantly higher than those in the survival group, while the serum level of Na+ (128.9±14.1 vs 133.8±9.3 mmol/L) was significantly lower (all P＜0.001). The optimal cut-off value of MELD score and serum level of PCT in predicting short-term mortality were 24.8 and 0.65 μg/L. The area under the ROC (AUC) of combined MELD score and PCT (0.880) was higher than that of only MELD score (0.820) or PCT (0.803), respectively (both P＜0.001). Conclusion MELD score combined with serum PCT achieves a predictive value for the short-term prognosis in patients with HBV-related ACLF.

Key words: Chronic hepatitis B, Acute-on-chronic liver failure, Prognosis, Model for end-stage liver disease, Procalcitonin

李华. MELD评分联合血清降钙素原评估乙型肝炎相关慢加急性肝衰竭患者短期预后的价值[J]. 肝脏, 2017, 22(3): 210-213.

LI Hua. Predictive value of MELD score combined with serum procalcitonin on the short-term prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Chinese Hepatolgy, 2017, 22(3): 210-213.

参考文献

[1] 吴婧,倪鎏达,江浦柱.MELD-EHBF模型建立及其对ACLF预后价值.肝脏,2015,20:447-461.
[2] 叶佩燕,杨宗国,陈晓蓉,等.HBV相关慢加急性肝衰竭不同分期的预后评价及影响因素分析.临床肝胆病杂志,2013,29:270-275.
[3] Kamath PS, Wisener RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology,2001,33:464-470.
[4] Zhou Q, Tan DM, Yi ZQ, et al. Prognostic value of procalcitonin, endotoxin and common inflammatory markers combining MELD score in patients with chronic severe hepatitis. Cent S Univ Med Sci,2013,38:388-394.
[5] 中华医学会感染病学会肝衰竭与人工肝学组,中华医学会肝病学会重型肝病与人工肝学组.肝衰竭诊疗指南.中华肝脏病杂志,2006,14:643-646.
[6] 中华医学会感染病学会肝衰竭与人工肝学组,中华医学会肝病学会重型肝病与人工肝学组.肝衰竭诊指治南(2012年版).中华肝脏病杂志,2013,21:177-183.
[7] Zheng MH, Shi KQ, Lin XF, et al. A model to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure using artificial neural network. J Viral Hepat,2013,20:248-255.
[8] Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl,2005,11:336-343.
[9] Huo TI, Lin HC, Huo SC, et al. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl,2008,14:837-844.
[10] Zaman MB, Hoti E, Qasim A, et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant Proc,2006,38:2097-2098.
[11] Garg H, Kumar A, Garg V, et al. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis,2012,44:166-171.
[12] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识.中华急诊医学杂志,2012,21:944-951.
[13] Pieri G, Agarwal B, Burroughs AK. C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol,2014,27:113-120.
[14] Whang KT, Vath SD, Becker KL, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock,2000,14:73-79.

[1]	王建文, 刘大东, 马鸿杰. 慢加急性肝衰竭合并侵袭性真菌感染患者的临床特征和预后影响因素分析[J]. 肝脏, 2020, 25(5): 507-509.
[2]	王敏. 肝癌患者自发性破裂出血的影响因素及预后因素分析[J]. 肝脏, 2020, 25(5): 510-513.
[3]	刘栋, 苏康乐, 张翠杰, 翟亚玲, 李芳华. 肾小管HBAg阳性表达与HBV相关肾功能损伤预后的关系[J]. 肝脏, 2020, 25(4): 372-374.
[4]	高朋彬, 郑欢伟, 赵晓彦, 王德华, 秦浩, 孟明辉, 张建集, 闫双缓. 内科综合治疗HBV-ACLF患者的临床特点及转归[J]. 肝脏, 2020, 25(4): 375-378.
[5]	赵梦, 陈明, 王丽, 胡孙裔. 自身免疫性肝炎患儿临床特点与预后[J]. 肝脏, 2020, 25(4): 379-381.
[6]	王雨, 许达峰, 周开伦, 武金才, 丁驿超, 古海强, 谢明微, 林明花. TLR4和肠道菌群在原发性肝癌进展中动态变化及与预后的关系[J]. 肝脏, 2020, 25(3): 273-276.
[7]	余守江, 王国兴, 马兰芳. TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J]. 肝脏, 2020, 25(3): 294-296.
[8]	李亚飞, 闫华楠, 韩少静, 郭永泽, 韩书香, 李淑霞, 吉丽, 张宏伟. 老年急性药物性肝损伤临床特征及预后影响因素分析[J]. 肝脏, 2020, 25(3): 319-322.
[9]	原庆会, 何伟. Vimentin在肝细胞癌组织中的表达及其与临床预后的关系[J]. 肝脏, 2020, 25(2): 199-201.
[10]	袁宏香, 张秋云, 娄金丽, 于艳华, 赵艳. 慢加急性肝衰竭血小板减少患者血栓弹力图及常规凝血指标的变化[J]. 肝脏, 2020, 25(1): 20-23.
[11]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.
[12]	张志侨, 叶一农, 何纲, 王鹏, 李静, 吴兴柳. 乙型肝炎相关慢加急性肝衰竭患者急性肾损伤的影响因素和高危人群分析[J]. 肝脏, 2019, 24(9): 997-1001.
[13]	刘亚迪, 孙双双, 徐浩, 李成忠. HBV相关慢加急性肝衰竭患者感染特点及危险因素分析[J]. 肝脏, 2019, 24(9): 1015-1019.
[14]	刘莉, 吕蓉蓉, 陈光耀, 邹佳丽, 盛佳琪. 35例小儿肝功能衰竭PE联合CVVHDF技术治疗的疗效及预后分析[J]. 肝脏, 2019, 24(9): 1028-1031.
[15]	诸海军, 万健, 孙莲娜, 孙杰, 陈嵩. WBC、IL-6及NLR值对慢加急性肝衰竭患者的早期预警价值[J]. 肝脏, 2019, 24(9): 1076-1078.